Skip to main content

Table 2 Mean Change in BPI–Severity and BPI–Interference Items during the Extension Phase

From: Maintenance of effect of duloxetine in Chinese patients with pain due to osteoarthritis: 13-week open-label extension data

Variable DLX_DLX PLA_DLX
N = 166 N = 175
Baseline Change Baseline Change
Average pain 3.3 (1.8) −1.0 (1.7)*** 3.7 (1.8) −1.4 (1.6)***
Worst pain 4.2 (2.1) −1.1 (2.0)*** 4.8 (1.9) −1.6 (1.7)***
Least pain 2.2 (1.9) −0.9 (1.6)*** 2.5 (1.9) −1.0 (1.7)***
Right now pain 2.8 (2.1) −1.1 (1.7)*** 3.3 (2.1) −1.4 (1.7)***
Average Interference 1.9 (1.8) −0.6 (1.1)*** 2.2 (1.7) −0.8 (1.2)***
General activity 3.0 (2.3) −0.9 (1.9)*** 3.6 (2.2) −1.3 (1.9)***
Mood 1.2 (2.0) −0.4 (1.2)*** 1.6 (2.1) −0.6 (1.7)***
Walking ability 3.0 (2.2) −0.9 (1.6)*** 3.5 (2.2) −1.3 (1.7)***
Normal work 2.6 (2.3) −0.9 (1.8)*** 3.1 (2.2) −1.1 (1.9)***
Relations with other people 0.8 (1.8) −0.2 (1.1)** 0.9 (1.7) −0.3 (1.2)**
Sleep 1.3 (2.2) −0.5 (1.7)*** 1.5 (2.1) −0.5 (1.6)***
Enjoyment of life 1.2 (2.1) −0.5 (1.5)*** 1.2 (2.0) −0.5 (1.6)***
  1. **p < 0.01; ***p < 0.001 (within-group, 2-sided t-test). Data are shown as mean (standard deviation). Baseline is the last non-missing observation during the placebo-controlled phase. Change is the change from the last non-missing observation during the placebo-controlled phase to the last non-missing observation during the extension phase
  2. Abbreviations: BPI Brief Pain Inventory, DLX duloxetine, PLA placebo